Payment overview · 2025
General Payments
$6,430.14
68 reported records · 16 companies
Healthcare provider profile · identity verified
Douglas E Schultz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHEBORO, NC · NPI 1487631859
Verified facts
What the public records show
CMS Open Payments records show Douglas E Schultz, MD received $6,430.14 in general payments during 2025 across 68 reported records.
GENZYME CORPORATION accounted for 82.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 335 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $5,304.00 | 82.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $333.17 | 5.2% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.18 | 2.6% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $149.87 | 2.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.53 | 1.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.84 | 1.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.92 | 1.3% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $41.67 | 0.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.58 | 0.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.68 | 0.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.65 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.34 | 0.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.76 | 0.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.32 | 0.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.98 | 0.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.65 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,304.00 | 1 |
| Food and Beverage | $1,126.14 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | GENZYME CORPORATION | $5,304.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $145.43 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.45 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.64 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.77 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.81 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.95 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.09 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.34 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.42 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.14 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 335 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
335 | 63 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 774 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 725 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 175 |
| Alprazolam | Alprazolam | 595 | 111 |
| Lisinopril | Lisinopril | 452 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 391 | 90 |
| Furosemide | Furosemide | 375 | 121 |
| Omeprazole | Omeprazole | 374 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 90 |
| Gabapentin | Gabapentin | 345 | 84 |
| Eliquis | Apixaban | 335 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 328 | 111 |
| Ezetimibe | Ezetimibe | 326 | 91 |
| Metformin Hcl | Metformin Hcl | 303 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 86 |
| Prednisone | Prednisone | 267 | 187 |
| Losartan Potassium | Losartan Potassium | 232 | 63 |
| Tramadol Hcl | Tramadol Hcl | 220 | 51 |
| Simvastatin | Simvastatin | 216 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 49 |
| Alendronate Sodium | Alendronate Sodium | 193 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 49 |
| Famotidine | Famotidine | 181 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 25 |
| Meloxicam | Meloxicam | 150 | 47 |
| Potassium Chloride | Potassium Chloride | 150 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 44 |
| Glimepiride | Glimepiride | 147 | 49 |
| Memantine Hcl | Memantine Hcl | 142 | 36 |
| Fenofibrate | Fenofibrate | 135 | 32 |
| Sertraline Hcl | Sertraline Hcl | 135 | 35 |
| Donepezil Hcl | Donepezil Hcl | 132 | 40 |
| Trazodone Hcl | Trazodone Hcl | 131 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 27 |
| Farxiga | Dapagliflozin Propanediol | 125 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 30 |
| Carvedilol | Carvedilol | 123 | 33 |
| Montelukast Sodium | Montelukast Sodium | 121 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 121 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 28 |
| Allopurinol | Allopurinol | 114 | 32 |
| Azithromycin | Azithromycin | 104 | 78 |
| Meclizine Hcl | Meclizine Hcl | 98 | 43 |
| Lorazepam | Lorazepam | 95 | 16 |
| Temazepam | Temazepam | 93 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 64 |
| Pregabalin | Pregabalin | 85 | 15 |
| Buspirone Hcl | Buspirone Hcl | 84 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 34 |
| Azelastine Hcl | Azelastine Hcl | 79 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 56 |
| Jardiance | Empagliflozin | 78 | 17 |
| Ozempic | Semaglutide | 78 | 15 |
| Valsartan | Valsartan | 76 | 24 |
| Amoxicillin | Amoxicillin | 75 | 65 |
| Levofloxacin | Levofloxacin | 75 | 60 |
| Nystatin | Nystatin | 74 | 26 |
| Synthroid | Levothyroxine Sodium | 74 | 16 |
| Atenolol | Atenolol | 73 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 22 |
| Finasteride | Finasteride | 67 | 18 |
| Fluconazole | Fluconazole | 67 | 38 |
| Ibuprofen | Ibuprofen | 65 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 17 |
| Valacyclovir | Valacyclovir Hcl | 63 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 13 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 12 |
| Celecoxib | Celecoxib | 54 | 23 |
| Promethazine Hcl | Promethazine Hcl | 54 | 18 |
| Torsemide | Torsemide | 52 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | suppressed |
| Mirtazapine | Mirtazapine | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 11 |
| Ondansetron Odt | Ondansetron | 49 | 28 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 47 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Linzess | Linaclotide | 44 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Estradiol | Estradiol | 42 | 11 |
| Methocarbamol | Methocarbamol | 42 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Spironolactone | Spironolactone | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 27 |
| Diazepam | Diazepam | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Glipizide Er | Glipizide | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 22 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Risperidone | Risperidone | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,430.14 · 68 records | GENZYME CORPORATION | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, GARDASIL 9, JARDIANCE, KISUNLA, KRYSTEXXA, LEQEMBI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error